List of Excipients in Branded Drug LITHOBID

Company	Tradename	Ingredient	NDC	Excipient	Potential Generic Entry
ANI Pharmaceuticals Inc	LITHOBID	lithium carbonate	62559-280	CALCIUM STEARATE
ANI Pharmaceuticals Inc	LITHOBID	lithium carbonate	62559-280	CARNAUBA WAX
ANI Pharmaceuticals Inc	LITHOBID	lithium carbonate	62559-280	FD&C BLUE NO. 2
ANI Pharmaceuticals Inc	LITHOBID	lithium carbonate	62559-280	FD&C RED NO. 40
ANI Pharmaceuticals Inc	LITHOBID	lithium carbonate	62559-280	FD&C YELLOW NO. 6
ANI Pharmaceuticals Inc	LITHOBID	lithium carbonate	62559-280	HYDROXYPROPYL CELLULOSE

Lithobid Excipient Strategy and Commercial Opportunities

Last updated: September 24, 2026

Lithobid is an extended-release lithium carbonate tablet used for bipolar disorder. Its commercial value is driven less by active-ingredient novelty than by controlled release, dose consistency, manufacturing reliability, and substitution economics. The strongest excipient opportunities are in matrix design, coating performance, moisture control, tablet robustness, and lower-risk alternatives to legacy excipients.

Lithobid is a conventional small-molecule prescription product, not a biologic. Biosimilar provisions do not apply. Generic competition is governed primarily by abbreviated new drug application requirements, therapeutic equivalence, bioequivalence, manufacturing capacity, and state substitution rules.

What is Lithobid and how does its formulation work?

Lithobid contains lithium carbonate in an extended-release tablet. The product is administered orally and is designed to reduce peak-to-trough exposure compared with immediate-release lithium carbonate. The FDA label warns that lithium has a narrow therapeutic range and that serum concentrations are affected by renal function, sodium balance, hydration, drug interactions, and formulation changes.[1]

What excipients are used in Lithobid?

The Lithobid labeling identifies a conventional solid-dose excipient system that includes:

Excipient category	Lithobid label ingredients	Primary function
Binder and granulation aid	Povidone, acacia	Granule strength and tablet integrity
Diluent	Lactose monohydrate	Tablet mass and compressibility
Disintegrant	Crospovidone	Mechanical breakup of non-matrix portions
Glidant	Colloidal silicon dioxide	Powder flow and content uniformity
Lubricant	Magnesium stearate	Ejection and tooling protection
Surfactant	Sodium lauryl sulfate	Wetting and dissolution support
Processing aid	Talc	Anti-adherence and flow
Coating components	Hypromellose and titanium dioxide are used in film-coating systems for comparable lithium carbonate ER presentations	Appearance, protection, swallowability, and moisture control

The exact excipient declaration should be checked against the current FDA-approved Lithobid labeling and package configuration. Excipients can differ by strength, manufacturer, and manufacturing site.[1]

The formulation strategy is functional rather than novel. It uses established pharmaceutical excipients with broad regulatory histories. The commercial barrier is therefore unlikely to be ownership of a proprietary excipient. The barrier is reproducing the release profile and product performance consistently at scale.

What excipient strategy is most important for Lithobid?

The core strategy is to control lithium release without creating excessive tablet size, dose dumping risk, or manufacturing variability. Lithium carbonate is highly soluble, and extended release requires sufficient control of liquid penetration, diffusion, erosion, or a combination of mechanisms.

Matrix-control strategy

A commercial successor or reformulation could use:

• Hydrophilic polymers such as hypromellose to form a gel barrier.
• Hydrophobic matrix materials to slow water ingress.
• Lipid-based excipients to reduce burst release.
• Polymer combinations that separate initial wetting from sustained diffusion.
• Coating systems that provide an additional release barrier.

The main technical risk is that a small change in polymer viscosity, particle size, compression force, or tablet porosity can alter dissolution. Lithium products require tight control because a faster release profile may increase peak exposure, while an overly slow profile may reduce therapeutic performance.

Particle-size and granulation control

Lithium carbonate particle size affects blend uniformity, dissolution, segregation, and compression. A robust strategy should define:

• Active pharmaceutical ingredient particle-size distribution.
• Granulation endpoint.
• Moisture target after drying.
• Blend time and order of excipient addition.
• Lubrication time.
• Compression force and tablet porosity.

A direct-compression process may lower cost but can increase segregation and flow risk. Wet granulation can improve uniformity and tablet strength, but it adds water exposure, drying controls, and process complexity.

Coating strategy

The coating is commercially relevant even when it does not control release. It can improve:

• Swallowability.
• Tablet identification.
• Resistance to abrasion.
• Protection against moisture.
• Patient acceptance.
• Packaging stability.

A film-coating supplier could create value through low-weight coatings, faster processing, lower solvent use, titanium-dioxide alternatives, or improved barrier properties. A coating that materially changes dissolution, however, may create a new bioequivalence and regulatory burden.

What formulations are protected by Lithobid patents?

Lithobid does not have the patent profile of a recently approved modified-release product. Lithium carbonate is an old active ingredient, and the principal commercial protection is associated with the product formulation, regulatory approval, manufacturing know-how, and brand recognition.

The FDA Orange Book is the relevant source for active patents and regulatory exclusivity linked to approved drug products.[2] A current Orange Book review should distinguish:

1. Patents listed for Lithobid itself.
2. Patents listed for other lithium carbonate extended-release products.
3. Unlisted manufacturing or process patents.
4. Patent claims that have expired.
5. Regulatory exclusivity that has ended.

For an old lithium carbonate product, the practical conclusion is that excipient suppliers should not assume freedom from competition depends on a Lithobid patent license. A differentiated excipient platform would need to create value through improved performance, lower cost, or a separate formulation claim rather than relying on legacy brand protection.

Are there formulation patents for lithium carbonate extended-release tablets?

Formulation patents may cover:

• Specific polymer ratios.
• Coated matrix tablets.
• Multiparticulate systems.
• Controlled-release granules.
• Osmotic delivery systems.
• Narrow dissolution profiles.
• Manufacturing processes linked to release performance.
• Stability improvements under high humidity.

The existence of a patent does not establish a blocking position. Claim scope, expiration, prosecution history, terminal disclaimers, maintenance fees, and the formulation used by a proposed entrant determine commercial relevance.

When does Lithobid lose exclusivity?

Lithobid has no remaining new-chemical-entity exclusivity. Lithium carbonate has been used clinically for decades, and generic lithium carbonate products are commercially available.

The principal exclusivity milestones are:

Regulatory asset	Commercial status
New chemical entity exclusivity	Expired
Orphan-drug exclusivity	Not applicable to the conventional Lithobid approval
Biologic exclusivity	Not applicable
Pediatric exclusivity	No current strategic relevance identified
Brand formulation protection	Limited to any surviving listed patents or enforceable formulation claims
Generic competition	Established in lithium carbonate immediate-release and extended-release markets

The absence of NCE exclusivity does not eliminate brand value. Lithobid can retain demand through prescriber familiarity, supply reliability, patient stability, and pharmacy preference. Those advantages are vulnerable when generic products have lower acquisition cost and broad distribution.

What is the Orange Book status of Lithobid?

Lithobid is an FDA-approved prescription product. Its relevant Orange Book issues are approval status, reference-product designation, therapeutic equivalence listings for competing products, and any patent or exclusivity entries.[2]

For a generic applicant, the central questions are:

• Whether the target product can reference the appropriate FDA-listed product.
• Whether the dosage form and release characteristics are therapeutically equivalent.
• Whether any listed patent remains enforceable.
• Whether a Paragraph IV certification is required.
• Whether a Paragraph III certification delays approval until patent expiration.
• Whether the applicant can establish bioequivalence under FDA guidance.

Because the active ingredient is old and generic lithium products are established, regulatory execution is likely more important than chemical novelty.

Which companies are challenging Lithobid?

Generic lithium carbonate manufacturers and contract manufacturers compete with Lithobid through approved immediate-release and extended-release products. Public FDA listings identify approved applicants, but the competitive set changes as products are approved, discontinued, or placed on temporary supply interruption.

The principal competitor groups are:

• Large generic manufacturers with broad psychiatric portfolios.
• Specialty pharmaceutical companies focused on hospital and chronic-care products.
• Authorized distributors and private-label suppliers.
• Contract development and manufacturing organizations with modified-release tablet capacity.

No biosimilar company is relevant. Lithium carbonate is a synthetic small molecule and is not regulated through the biosimilar pathway.

What Paragraph IV challenges and litigation affect Lithobid?

A Paragraph IV certification applies when an ANDA applicant asserts that a listed patent is invalid, unenforceable, or not infringed. It is relevant only if an active patent is listed for the reference product.

For an old lithium carbonate extended-release product, litigation risk is generally lower than for a new branded extended-release medicine because:

• The active ingredient is long established.
• Generic products already exist.
• Any relevant patents are likely formulation or process patents.
• The value of a remaining patent must be weighed against the low-cost generic market.

A Paragraph IV filing can still create litigation if a brand owner identifies a commercially meaningful formulation patent. The key diligence items are the complaint date, the 30-month stay position, the asserted claims, ANDA product characteristics, and any settlement terms.

The cited FDA sources do not establish a current material Lithobid settlement or active patent litigation event. Commercial diligence should separate litigation involving Lithobid from disputes involving unrelated lithium carbonate products.

How strong is the Lithobid patent estate?

The patent estate appears structurally weaker than estates for recently launched modified-release drugs. Its likely strengths are regulatory familiarity and manufacturing know-how, not long-duration exclusivity.

Estate element	Relative position
Active-ingredient patents	Weak or expired
NCE exclusivity	None
Basic extended-release concept	Vulnerable to prior art
Narrow polymer or coating claims	Potentially relevant if unexpired
Manufacturing know-how	Potentially valuable but difficult to enforce
Brand and prescriber recognition	Commercially useful but not patent protection
Supply reliability	Important market differentiator

A new excipient supplier should therefore focus on technical performance that can be documented in comparative dissolution, stability, process capability, and cost-of-goods studies.

What commercial opportunities exist for Lithobid excipients?

1. Controlled-release polymer systems

A supplier can pursue a polymer platform that provides equivalent or improved release with lower use levels, simpler processing, or better lot-to-lot consistency. The strongest opportunity is a formulation that reduces sensitivity to compression force and tablet porosity.

2. Lactose-reduced or lactose-free formulations

Lactose is a common diluent, but some manufacturers seek alternatives because of patient intolerance, supply management, or product-positioning requirements. Candidate diluents include microcrystalline cellulose, mannitol, dibasic calcium phosphate, and co-processed excipients.

The replacement must preserve tablet weight, hardness, dissolution, and content uniformity. Changing the diluent can alter lithium release even when the polymer system is unchanged.

3. Improved moisture protection

Lithium products can be sensitive to environmental and patient-use conditions because hydration and sodium balance affect clinical exposure, while formulation moisture can affect physical stability and dissolution. Barrier coatings, high-performance blister packaging, desiccant systems, and low-moisture excipient grades can support a differentiated stability package.

4. Direct-compression excipients

A co-processed filler-binder or high-functionality excipient could reduce granulation steps, shorten cycle time, and improve tablet strength. The business case depends on whether the excipient lowers total manufacturing cost without changing the dissolution profile.

5. Titanium-dioxide and talc alternatives

Regulatory and customer preferences can create demand for alternative opacifiers, colorants, and anti-adherents. Such substitutions are commercially feasible but may require new stability, appearance, extractables, and process data.

6. Smaller-tablet and dose-flexibility platforms

Lithium therapy often requires individualized dosing and serum monitoring. A smaller tablet, improved swallowability, or a robust scored configuration could support patient adherence and pharmacy handling. Any scoring change must be evaluated for dose uniformity and release performance.

What generic entry risks exist for Lithobid?

Generic entry risk is high because the product is an old small-molecule therapy with established alternatives. The main risks are:

• Price erosion after additional generic approvals.
• Pharmacy substitution.
• Wholesaler inventory preference.
• Manufacturing interruptions.
• Formulation changes that alter bioequivalence.
• Patient switching concerns related to serum lithium monitoring.
• Contracting pressure from health plans and government programs.

Brand retention is more likely when Lithobid has reliable supply, consistent tablet performance, and strong prescriber confidence. Excipient changes that trigger product variability can weaken those advantages.

How does Lithobid compare with immediate-release lithium carbonate?

Factor	Lithobid extended release	Immediate-release lithium carbonate
Dosing objective	Smoother exposure and reduced dosing frequency in appropriate patients	Faster release and flexible titration
Formulation complexity	Higher	Lower
Excipient value	High because release control is critical	Primarily compression, stability, and tolerability
Bioequivalence risk	Higher	Lower, depending on product
Manufacturing barrier	Modified-release process and dissolution control	Conventional solid-dose manufacturing
Patent opportunity	Narrow release, coating, or process claims	Limited
Generic competition	Established	Established

Lithobid competes on formulation behavior and clinical familiarity. An excipient strategy that makes the extended-release product easier to manufacture without changing exposure has greater commercial value than a simple cost reduction.

What FDA regulatory issues apply to Lithobid excipient changes?

A material excipient change can require comparative dissolution, stability studies, manufacturing validation, and potentially a supplemental filing or new ANDA strategy. The regulatory impact depends on:

• Identity and level of the changed excipient.
• Effect on release rate.
• Effect on impurity profile and stability.
• Change in manufacturing process.
• Product-strength applicability.
• Whether the change is post-approval or part of a new generic development program.

FDA’s SUPAC framework provides a general structure for evaluating post-approval changes to immediate-release and modified-release solid oral products.[3] Modified-release products generally require stronger dissolution controls than immediate-release tablets.

What is the revenue exposure and commercial outlook?

Lithobid-specific revenue is not generally disclosed as a separate public line item. The product operates in a mature, price-sensitive market where unit volume can remain substantial while brand revenue declines under generic substitution.

The excipient opportunity is therefore primarily business-to-business. A supplier can monetize:

• Qualification into a generic manufacturer’s platform.
• Second-source supply for critical excipients.
• Reformulation support.
• Process optimization.
• Stability improvement.
• Private-label product development.
• Global expansion into markets with limited lithium supply.

The most attractive customers are manufacturers that need a reliable extended-release platform but do not want to develop a full matrix and coating system internally.

Key Takeaways

• Lithobid is an extended-release lithium carbonate tablet with no biologic or biosimilar pathway.
• Its main formulation challenge is controlling release of a highly soluble active ingredient.
• The commercial excipient opportunity lies in polymer matrices, moisture protection, direct compression, and robust coating systems.
• Generic entry risk is high because lithium carbonate is an old active ingredient and competing products are established.
• Patent value is likely concentrated in narrow formulation, process, or manufacturing claims rather than active-ingredient protection.
• A successful excipient platform must demonstrate dissolution equivalence, process robustness, stability, and lower total manufacturing cost.
• Brand revenue is exposed to substitution, but supply reliability and consistent product performance can preserve commercial value.

FAQs

Can Lithobid be reformulated with different excipients?

Yes. A reformulation can use alternative binders, diluents, lubricants, polymers, coatings, or moisture-barrier systems. The change must preserve release performance, stability, content uniformity, and bioequivalence requirements.

Is lithium carbonate an attractive excipient-development target?

Yes, particularly for extended-release systems. The active ingredient is inexpensive, but its narrow therapeutic range increases the value of reliable dissolution control and manufacturing consistency.

Are there biosimilar risks for Lithobid?

No. Lithium carbonate is a synthetic small molecule. Competition proceeds through generic drug pathways rather than biosimilar applications.

Can a new polymer create patent protection around a Lithobid generic?

Potentially. Protection may arise from a specific polymer composition, ratio, coating structure, release profile, or manufacturing process. Patentability depends on novelty, non-obviousness, written description, and claim scope.

What is the highest-value commercial improvement for a Lithobid substitute?

The strongest opportunity is a controlled-release formulation that matches the reference product while reducing manufacturing variability, improving moisture stability, lowering tablet weight, or reducing total cost of goods.

References

1. U.S. Food and Drug Administration. (n.d.). Lithobid (lithium carbonate) extended-release tablets: Prescribing information. DailyMed.

2. U.S. Food and Drug Administration. (n.d.). Approved drug products with therapeutic equivalence evaluations. FDA Orange Book.

3. U.S. Food and Drug Administration. (1995). SUPAC-MR: Modified release solid oral dosage forms: Scale-up and postapproval changes. Center for Drug Evaluation and Research.